Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

Charlotte Charpentier, Bénédicte Roquebert, Olivier Delelis, Lucile Larrouy, Sophie Matheron, Roland Tubiana, Marina Karmochkine, Xavier Duval, Geneviève Chêne, Alexandre Storto, Gilles Collin, Antoine Bénard, Florence Damond, Jean-François Mouscadet, Françoise Brun-Vézinet, Diane Descamps
Antimicrobial Agents and Chemotherapy 2011, 55 (3): 1293-5
We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"